Qualigen Therapeutics Inc. (AIXC)
Market Closed
30 Jul, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
0. 67
+0.02
+3.1077%
$
4.24M Market Cap
- P/E Ratio
- Div Yield
28,328 Volume
-2.7 Eps
$ 0.65
Previous Close Want to track AIXC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
AIXC closed today higher at $0.67, an increase of 3.1077% from yesterday's close, completing a monthly decrease of -46.8095% or -$0.59. Over the past 12 months, AIXC stock lost -72.075%.
AIXC is not paying dividends to its shareholders.
The last earnings report, released on May 19, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Qualigen Therapeutics Inc. has completed 4 stock splits, with the recent split occurring on Nov 05, 2024.
The company's stock is traded on one exchange.
AIxCrypto Holdings, Inc. (AIXC) Q1 2026 Earnings Call Prepared Remarks Transcript
AIxCrypto Holdings, Inc. (AIXC) Q1 2026 Earnings Call Prepared Remarks Transcript
Seekingalpha | 2 months ago
Qualigen Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $4 | $0.77 | -$3.23 | -80.75% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 325 | $1,108.25 | $238.65 | -$869.6 | -78.47% |
 Hui Fai Tam Caitong International Asset Management Co. Ltd. | 1 | $1.25 | $0.69 | -$0.56 | -44.8% |
Qualigen Therapeutics Inc. (AIXC) FAQ
What is the stock price today?
The current price is $0.67.
On which exchange is it traded?
Qualigen Therapeutics Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is AIXC.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 4.24M.
Has Qualigen Therapeutics Inc. ever had a stock split?
Qualigen Therapeutics Inc. had 4 splits and the recent split was on Nov 05, 2024.
Qualigen Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Jiawei Wang CEO | NASDAQ (CM) Exchange | 74754R301 CUSIP |
| US Country | 4 Employees | - Last Dividend | 5 Nov 2024 Last Split | 24 Jun 2015 IPO Date |
Overview
Qualigen Therapeutics, Inc. is a biotechnology firm established in 1996 and headquartered in Carlsbad, California. The company is committed to developing and commercializing innovative treatments for cancer and infectious diseases. Leveraging its expertise in biotechnology, Qualigen Therapeutics focuses on bringing novel therapeutic products to market, aiming to address some of the most challenging medical conditions with a focus on quality and speed. Their cutting-edge approach includes the development of drugs and therapeutic devices, heavily relying on both proprietary technologies and innovative research in the field.
Products and Services
- FastPack System - A patented, rapid onsite immunoassay testing system designed to improve diagnostic efficiency and accuracy. This product underscores the company's commitment to advancing diagnostic technologies alongside therapeutic products.
- QN-302 - Currently under development, QN-302 is targeted for the treatment of pancreatic ductal adenocarcinoma, a challenging and often deadly form of cancer. This exemplifies Qualigen's focus on targeted cancer therapies.
- QN-247 - An oligonucleotide-based drug candidate intended to treat a variety of cancers that express nucleolin, including both liquid and solid tumors. This approach reflects the company's strategy to tackle cancer through innovative molecular targeting.
- QN-165 - A drug candidate viewed as a potential broad-spectrum solution for infectious diseases, including COVID-19. Its development underscores the company's commitment to addressing urgent global health challenges.
- RAS-F - A small-molecule inhibitor targeting the RAS oncogene protein-protein interactions. By blocking RAS mutations and inhibiting tumor formation, RAS-F represents a novel approach to cancer treatment, reflecting Qualigen's focus on cutting-edge research in oncology.
- Selective Target Antigen Removal System - This therapeutic device is designed to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints from the body. It highlights Qualigen's innovative approach to treatment, aiming at directly eliminating the sources of disease.
Contact Information
Address: 5857 Owens Avenue
Phone: 760 452 8111
Website: https://www.aixcrypto.ai
